Richard Branson and Emma Walmsley are two prominent British business figures, but there is no verified public record showing a direct personal relationship, family connection, shared board role, or formal business partnership between them. The clearest documented link is indirect: both became connected to 23andMe at different points, Branson through Virgin Group’s 2021 SPAC transaction and Walmsley through GSK’s pharmaceutical research partnership and investment in the genetics company.
That distinction matters because searches combining their names can make the relationship appear closer than the evidence supports. Their careers have overlapped broadly in British business, healthcare, investment and purpose-led corporate leadership, but the available records do not establish that Branson and Walmsley personally worked together.
Is There a Direct Richard Branson and Emma Walmsley Connection?
There is no confirmed direct connection between Richard Branson and Emma Walmsley in the form of a joint company, shared directorship, family relationship, or publicly documented personal partnership.
Branson is the founder of the Virgin Group, a diversified investment and brand group whose businesses have operated across travel, telecommunications, financial services, health and wellness, entertainment, real estate and space. Virgin states that its brand originated in 1970 and today extends across dozens of companies internationally.
Walmsley built her career primarily in consumer products and pharmaceuticals. She joined GlaxoSmithKline, now known as GSK, in 2010 after 17 years at L’Oréal and became GSK’s chief executive in April 2017.
Their main identifiable crossover comes through an entirely separate company: 23andMe.
The 23andMe Link Between Branson, Virgin and GSK
The strongest factual connection between the two business figures can be traced through 23andMe, the genetics and consumer-health company.
GSK’s relationship with 23andMe under Emma Walmsley
In July 2018, while Emma Walmsley was GSK CEO, GSK and 23andMe announced a four-year exclusive research collaboration focused on using human genetics to identify potential drug targets and develop medicines.
Under the agreement:
- GSK gained access to research involving de-identified genetic and phenotypic data from consenting 23andMe participants.
- The companies established a joint drug-discovery programme.
- GSK made a $300 million equity investment in 23andMe.
- The original agreement included the possibility of extending the collaboration for an additional year.
GSK extended the exclusive discovery period through July 2023. By January 2022, 23andMe said the collaboration had already produced more than 40 genetically supported therapeutic programmes.
After the exclusive period ended, the companies announced another arrangement in October 2023. That agreement gave GSK a one-year, non-exclusive licence to use certain 23andMe data for drug-target discovery and related research.
This makes 23andMe a meaningful part of GSK’s research history during Walmsley’s leadership.
Richard Branson and 23andMe
Richard Branson’s connection appeared through a different route.
In February 2021, 23andMe announced that it would become publicly traded by merging with VG Acquisition Corp., a special-purpose acquisition company sponsored by Virgin Group.
The transaction valued 23andMe at an enterprise value of approximately $3.5 billion at announcement. Branson and 23andMe co-founder Anne Wojcicki each committed $25 million to the accompanying private investment in public equity, or PIPE.
The transaction was completed on June 16, 2021, according to subsequent U.S. Securities and Exchange Commission filings.
Does this mean Branson and Walmsley worked together?
No evidence establishes that conclusion.
The chronology is more accurately described this way:
| Year | Development | Relevant person |
|---|---|---|
| 2018 | GSK signs genetics and drug-discovery collaboration with 23andMe and invests $300 million | Emma Walmsley was GSK CEO |
| 2021 | Virgin-sponsored VG Acquisition Corp. agrees to merge with 23andMe | Richard Branson |
| 2021 | 23andMe public-market transaction closes | Richard Branson / Virgin-linked SPAC |
| 2022 | GSK extends exclusive discovery collaboration | Walmsley-led GSK |
| 2023 | GSK and 23andMe enter a further non-exclusive data-licensing arrangement | Walmsley-led GSK |
The two executives therefore had separate corporate relationships with the same company, but that should not be presented as proof that they had a direct partnership with one another.
Who Is Richard Branson?
Sir Richard Branson is a British entrepreneur best known for creating the Virgin brand.
Virgin traces its commercial origins to a mail-order record operation launched in 1970. It later expanded into Virgin Records before moving into industries such as aviation, financial services, telecommunications, hospitality and spaceflight.
Virgin’s official biography describes Branson as the founder of Virgin Group. It also records his 2021 flight aboard Virgin Galactic’s VSS Unity during the Unity 22 mission, which took him to the edge of space.
His business career differs substantially from Walmsley’s. Branson became known for building and licensing a consumer-facing brand across many industries rather than managing one large pharmaceutical corporation.
Virgin Group now describes itself primarily as a global growth investor with holdings across multiple asset classes and sectors. Its principal activity is investment management.
Who Is Emma Walmsley?
Dame Emma Walmsley is a British corporate executive best known for leading GSK from 2017 through the end of 2025.
Before entering pharmaceuticals, Walmsley spent 17 years at L’Oréal in marketing and management positions across the UK, Europe, the United States and China. She joined GSK in 2010 and eventually became head of its Consumer Healthcare business before being appointed group CEO.
The UK government described her as the first woman to lead a major global pharmaceutical company when announcing her damehood in the 2020 Birthday Honours.
Her period as GSK CEO included a major reshaping of the company. GSK separated its consumer-health operation, which subsequently became Haleon, while GSK itself placed increasing emphasis on vaccines, specialty medicines and research and development. When announcing Walmsley’s succession in September 2025, GSK specifically credited her with the company’s portfolio transformation and the creation of Haleon as a standalone consumer-health company.
Emma Walmsley’s Current Status After GSK
Walmsley ceased to be GSK CEO and a member of its board on December 31, 2025. Luke Miels became chief executive on January 1, 2026.
GSK retained Walmsley as an employee during a transition period that ran until September 30, 2026, with the company saying she would help with the leadership handover and provide support concerning geopolitical and technology-related issues. That period has therefore now ended as of October 1, 2026.
She remains active in corporate governance outside GSK. Microsoft’s fiscal-2026 Form 10-K lists Emma N. Walmsley as a Microsoft director, and an SEC ownership filing dated September 2026 also identifies her relationship to Microsoft as “Director.”
How Their Business Careers Differ
Although both became internationally known British business leaders, their routes to prominence are quite different.
Branson is fundamentally an entrepreneur, founder and investor. His career was built around creating new ventures, extending the Virgin brand into different industries and backing businesses in emerging or disruptive markets.
Walmsley is primarily a professional corporate executive and board director. Her career progressed through senior management at L’Oréal and GSK, culminating in responsibility for one of the world’s largest biopharmaceutical businesses.
Their organisational roles also differ:
| Area | Richard Branson | Emma Walmsley |
|---|---|---|
| Best known for | Founding Virgin | Former CEO of GSK |
| Main career model | Entrepreneur and investor | Corporate executive |
| Major industries | Travel, media, finance, hospitality, health, space | Consumer goods, pharmaceuticals, vaccines |
| 23andMe connection | Virgin-sponsored SPAC and personal PIPE investment | GSK research collaboration and investment during her CEO tenure |
| Current documented role | Virgin Group founder | Microsoft director |
| Direct partnership with each other | No verified evidence | No verified evidence |
Where Their Professional Interests Overlap
There are some broad areas in which their careers intersect conceptually even without a direct partnership.
Healthcare
Walmsley’s connection is straightforward. GSK develops vaccines and medicines and describes itself as a global biopharmaceutical company.
Branson’s Virgin portfolio has also included health and wellness businesses, although healthcare has never been his sole or primary field. Virgin currently lists health and wellness among the sectors in which Virgin Group invests.
The 23andMe episode provides the clearest example of their interests touching the same healthcare company from different directions.
Technology and data
Walmsley’s tenure at GSK included increased use of genetics, data and technology in drug discovery. GSK’s partnership with 23andMe explicitly aimed to use large-scale genetic information to improve target identification and medicine development.
Her continuing role on Microsoft’s board also places her within the governance of one of the world’s largest technology companies.
Branson, meanwhile, has repeatedly invested in technology-led ventures through Virgin and related investment vehicles, including the transaction that brought 23andMe to public markets.
Purpose-led business
Both have publicly associated business leadership with broader social goals, although through different structures.
Branson established Virgin Unite in 2004 as the Virgin Group’s nonprofit entrepreneurial foundation. Virgin describes its aim as using entrepreneurship and business to address social and environmental problems.
During Walmsley’s GSK leadership, the company was involved in areas including global access to medicines, vaccination, public health and environmental sustainability. GSK, for example, served as a principal partner of COP26 while Walmsley was chief executive.
These parallels describe broad leadership interests, not evidence of a joint initiative between the two.
Why Are Richard Branson and Emma Walmsley Searched Together?
The most plausible factual explanation is the network of major companies around them.
Both are highly visible British business figures. Both have been connected to health and technology businesses. Most importantly, their professional histories intersect indirectly through 23andMe.
That creates a legitimate corporate connection:
Emma Walmsley → GSK → 23andMe ← Virgin/VG Acquisition Corp. ← Richard Branson
What the evidence does not establish is a direct Branson-Walmsley partnership.
For accuracy, articles or profiles that describe them simply as “business partners” would therefore overstate what public records show.
FAQ
Are Richard Branson and Emma Walmsley related?
No verified information indicates that Richard Branson and Emma Walmsley are related. Their publicly documented family and professional backgrounds are separate.
Have Richard Branson and Emma Walmsley worked together?
There is no confirmed public record showing that they personally worked together on a company, board, investment or project. Their strongest identifiable business connection is indirect through 23andMe.
What does 23andMe have to do with Richard Branson and Emma Walmsley?
GSK entered a major genetics-research partnership with 23andMe in 2018 while Walmsley was CEO and invested $300 million in the company. In 2021, a Virgin Group-sponsored SPAC led by Richard Branson agreed to merge with 23andMe, and Branson personally committed $25 million to the associated PIPE financing.
Is Emma Walmsley still CEO of GSK?
No. She stepped down as CEO and from GSK’s board on December 31, 2025. Luke Miels became CEO on January 1, 2026, while Walmsley’s transition employment with GSK continued until September 30, 2026.
What does Emma Walmsley do now?
As of October 2026, her GSK transition period has ended. Recent SEC and Microsoft records confirm that she continues to serve as a director of Microsoft Corporation.
What is Richard Branson’s current role?
Virgin continues to identify Richard Branson as the founder of Virgin Group. The group operates as a diversified global investor while the Virgin brand remains active across numerous industries.
